Evidence map›Paper›PMID 33172554›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2020

[Clinical features of neuroblastoma: an analysis of 44 children].

Cheng-Guang Zhu, Xiang-Ling He, Zhi-Ge Tang, Ke-Ke Chen, Run-Ying Zou, Xin Tian, Ya-Lan You

Abstract read
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cheng-Guang ZhuDepartment of Pediatric Hematology and Oncology, Hunan Provincial People's Hospital, Changsha 410005, China. hexiangl@hunnu.edu.cn.
Xiang-Ling He
Zhi-Ge Tang
Ke-Ke Chen
Run-Ying Zou
Xin Tian
Ya-Lan You

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the clinical features of neuroblastoma (NB) and the factors influencing survival rate.

methodsA total of 44 children with NB who were admitted from April 2016 to February 2020 were enrolled as research subjects. A retrospective analysis was performed on their medical data and follow-up data.

resultsThe common clinical symptoms of these 44 children were fever (10/44, 23%), mass (9/44, 20%), abdominal pain (8/44, 18%), cough (7/44, 16%), pale complexion (3/44, 7%), claudication (2/44, 5%), and abnormal activity (2/44, 5%). According to the INSS stage, 2 children (4%) had stage I NB, 5 children (11%) had stage II NB, 5 children (11%) had stage III NB, and 32 children (73%) had stage IV NB. The mean follow-up time was (15.3±1.5) months, with a recurrence rate of 20% and an overall survival rate of 82%. Among the 44 children, 29 (66%) achieved event-free survival and 7 (16%) had survival with tumor. The univariate analysis showed that a pathological type of NB and an increase in serum neuron-specific enolase (NSE) decreased the overall survival rate of children with NB (P<0.05).

conclusionsThe clinical symptoms of children with NB are not specific at the first visit. Fever, abdominal pain, and mass are common symptoms, and there is a high proportion of children in the advanced stage. The pathological type of NB and an increase in serum NSE may be associated with a reduction in the overall survival rate of children with NB.

Indexed as

NeuroblastomaChildHumansInfantInfant, NewbornNeoplasm Recurrence, LocalNeoplasm StagingPhosphopyruvate HydrataseRetrospective StudiesSurvival RatePhosphopyruvate Hydratase

Identifiers

PMID33172554
PMCPMC7666396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.